Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Revelation Biosciences Reveals Encouraging Preclinical Data From Its Lead Fibrosis Candidate

Published 07/02/2023, 16:38
Updated 07/02/2023, 17:40
© Reuters.  Revelation Biosciences Reveals Encouraging Preclinical Data From Its Lead Fibrosis Candidate

© Reuters. Revelation Biosciences Reveals Encouraging Preclinical Data From Its Lead Fibrosis Candidate

Benzinga -

  • Revelation Biosciences Inc (NASDAQ: REVB) announced biomarker data from a preclinical model of acute and chronic kidney disease, supporting the potential clinical utility of REVTx-300 previously announced in November last year.
  • In this validated preclinical model, administration of REVTx-300 caused a significant reduction in circulating transforming growth factor-β (TGF-β) in a dose-dependent manner relative to the positive control group.
  • In addition, REVTx-300 significantly increased circulating anti-inflammatory interleukin-10, hepcidin, and neutrophil gelatinase-associated lipocalin in all groups in a dose-dependent manner relative to the positive control group.
  • There were no significant increases in markers of inflammation. Revelation plans to seek publication of the full results during 2023.
  • Revelation originally released positive results from the preclinical model of acute kidney injury and chronic kidney disease.
  • Additional analysis found that treatment with REVTx-300 significantly reduced new collagen deposition (fibrosis) in the renal cortex in a dose-dependent manner in the medium and high dose groups (42.1% reduction and 56.7%, respectively).
  • Price Action: REVB shares are up 0.72% at $8.66 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.